Skip to main content
Celon Pharma S.A. logo

Celon Pharma S.A. — Investor Relations & Filings

Ticker · CLN ISIN · PLCLNPH00015 LEI · 259400Q0ERJT0NC5DT24 WAR Manufacturing
Open in API
Filings indexed 709 across all filing types
Latest filing 2022-11-23 Interim / Quarterly Rep…
Country PL Poland
Listing WAR CLN

About Celon Pharma S.A.

https://celonpharma.com/en/

Celon Pharma S.A. is an integrated pharmaceutical company that conducts advanced research and manufactures modern drugs. The company is engaged in the development, production, distribution, and marketing of therapeutic solutions. Its primary focus is on developing treatments for cancers, neurological diseases, diabetes, and other metabolic disorders. As a marketing authorization holder, Celon Pharma manages the full product lifecycle, from scientific research and development to commercialization, aiming to improve patient health and quality of life.

Recent filings

Filing Released Lang Actions
Raport za 3 kwartał 2022 r.
Interim / Quarterly Report Classification · 100% confidence The document is a detailed financial report containing a table of contents, financial statements (income statement, balance sheet, cash flow), notes to the financial statements, and management commentary. It covers a specific period (period ended September 30, 2022) and includes comparative data for the previous year. The structure and content (e.g., 'Skrócone sprawozdanie finansowe' - Condensed Financial Report) clearly identify it as an interim/quarterly financial report. 9M 2022
2022-11-23 Polish
Zakwalifikowanie do dofinansowania projektu Celon Pharma S.A. w zakresie nowego celu terapeutycznego dla analogu białka FGF1 - Content (PL)
Capital/Financing Update Classification · 98% confidence The document is a formal announcement from the Management Board ('Zarząd') of Celon Pharma S.A. regarding the successful qualification of their project proposal for funding from the Medical Research Agency ('Agencja Badań Medycznych'). It details the project scope (drug development for metabolic diseases), the funding amount (approx. 27 million PLN out of 49 million PLN total cost), and the timeline (until October 2028). This announcement concerns a significant financing activity and capital structure update related to R&D funding. This fits best under 'Capital/Financing Update' (CAP), as it is a direct report on securing public funds for a major project. It is not an earnings release (ER), an interim report (IR), or a general regulatory filing (RNS), as it pertains specifically to financing/funding success.
2022-11-21 Polish
Zakwalifikowanie do dofinansowania projektu Celon Pharma S.A. w zakresie zwiększenia bezpieczeństwa lekowego poprzez wdrożenie w produkcji własnej Spółki innowacyjnych form doustnych produktów lecz...
Regulatory Filings Classification · 100% confidence The document is a formal announcement by the Management Board ('Zarząd') of Celon Pharma S.A. regarding the successful qualification of their project application for public funding from the Medical Research Agency ('Agencja Badań Medycznych'). The content details the project scope (developing cardiovascular drugs), the total cost (approx. 19.7 million PLN), and the awarded public funding amount (approx. 12.1 million PLN). This announcement concerns fundraising, financing activities, and capital structure changes related to R&D funding. This aligns best with the 'Capital/Financing Update' category (CAP), as it is a direct notification about securing significant external funding for corporate development, even if it is a grant rather than traditional debt or equity issuance.
2022-11-08 Polish
Raport okresowy - półrocze 2022
Interim / Quarterly Report Classification · 100% confidence The document is titled 'ŚRÓDROCZNE SKRÓCONE SPRAWOZDANIE FINANSOWE' (Interim Condensed Financial Report) for the 6-month period ending June 30, 2022. It contains detailed financial statements, including the Statement of Comprehensive Income, notes to the financial statements, and segment reporting. It is a comprehensive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). H1 2022
2022-09-29 Polish
Statut Spółki
Regulatory Filings Classification · 91% confidence The document text provided is titled "Statut Spółki 'CELON PHARMA' Spółka Akcyjna" (Statute of the Company 'CELON PHARMA' Joint Stock Company). It details the general provisions (§ 1 to § 5) and the subject of the company's activity (§ 6), listing various Polish PKD codes (classification of economic activities). This content is characteristic of a company's foundational legal document, such as its Articles of Association or Charter. None of the provided filing codes (AGM-R, 10-K, ER, IR, etc.) directly map to a corporate statute or charter document. However, the closest category that deals with the fundamental structure, rules, and governance of a company, especially when specific legal/governance filings are not available, is Governance Information (CGR), which covers internal rules and board structure. Since this is a foundational document defining the company's legal existence and scope, CGR is the most appropriate fit among the given options, although it is not a perfect match for a 'Statute'.
2022-09-14 Polish
Rejestracja zmiany Statutu Spółki - Content (PL)
Share Issue/Capital Change Classification · 95% confidence The document is a current report (raport bieżący) from a Polish company (Celon Pharma S.A.) detailing two main corporate actions registered on September 14, 2022: 1) The registration of a change in the Company's Statute (Statut) by the National Court Register (KRS), specifically adding a new business activity code (PKD 86.90.E). 2) The registration of a capital increase related to the issuance of Series C shares under a conditional capital increase program. The text explicitly mentions that the consolidated text of the Statute reflecting the change is attached as an appendix to the current report. Since the document primarily announces official corporate changes (statute amendment and capital increase registration) and mentions an attached document (the consolidated statute), it relates to significant structural and capital events. While it announces an attached document, the core content is the official notification of the registration of these changes. This type of filing, announcing registration of statute changes and capital structure updates, fits best under Capital/Financing Update (CAP) or potentially Regulatory Filings (RNS) if CAP is too specific. Given the explicit mention of 'podwyższenia kapitału zakładowego' (capital increase) and 'zmiany Statutu' (statute change), CAP is the most appropriate specific category. It is not an ER, IR, or 10-K as it is not a financial results report.
2022-09-14 Polish

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.